aran f. labrijn
Genmab (Netherlands)
Utrecht, Netherlands
Review Editor
Cancer Immunity and Immunotherapy
Genmab (Netherlands)
Utrecht, Netherlands
Review Editor
Cancer Immunity and Immunotherapy
Koç University Hospital
Istanbul, TĂĽrkiye
Review Editor
Cancer Immunity and Immunotherapy
National Institute of Oncology (NIO)
Budapest, Hungary
Review Editor
Cancer Immunity and Immunotherapy
Tampere University
Tampere, Finland
Review Editor
Cancer Immunity and Immunotherapy
Rush University
Chicago, United States
Review Editor
Cancer Immunity and Immunotherapy
University of Birmingham
Birmingham, United Kingdom
Review Editor
Cancer Immunity and Immunotherapy
Simon Fraser University
Burnaby, Canada
Review Editor
Cancer Immunity and Immunotherapy
Université de Bordeaux
Bordeaux, France
Review Editor
Cancer Immunity and Immunotherapy
Lonza (United States)
Walkersville, United States
Review Editor
Cancer Immunity and Immunotherapy
National Institutes of Health (NIH)
Bethesda, United States
Review Editor
Cancer Immunity and Immunotherapy
Ludwig Maximilian University of Munich
Munich, Germany
Review Editor
Cancer Immunity and Immunotherapy
Institute of Public Health, College of Pharmacy and Pharmaceutical Sciences, Florida Agricultural and Mechanical University
Tallahassee, United States
Review Editor
Cancer Immunity and Immunotherapy
St. John's University
Queens, United States
Review Editor
Cancer Immunity and Immunotherapy
Human Biology Division, Fred Hutchinson Cancer Research Center
Seattle, United States
Review Editor
Cancer Immunity and Immunotherapy
University of Maryland
Baltimore, United States
Review Editor
Cancer Immunity and Immunotherapy
Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea
Seoul, Republic of Korea
Review Editor
Cancer Immunity and Immunotherapy